A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

BACKGROUND: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Edward, Lovett-Racke, Amy E, Gormley, Matthew, Liu, Yue, Petracca, Maria, Cocozza, Sirio, Shubin, Richard, Wray, Sibyl, Weiss, Michael S, Bosco, Jenna A, Power, Sean A, Mok, Koby, Inglese, Matilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897779/
https://www.ncbi.nlm.nih.gov/pubmed/32351164
http://dx.doi.org/10.1177/1352458520918375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897779/
https://www.ncbi.nlm.nih.gov/pubmed/32351164
http://dx.doi.org/10.1177/1352458520918375

Ejemplares similares